As of 2024-12-11, the EV/EBITDA ratio of Calliditas Therapeutics AB (CALTX.ST) is -35.90. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. CALTX.ST's latest enterprise value is 12,678.51 mil SEK. CALTX.ST's TTM EBITDA according to its financial statements is -353.14 mil SEK. Dividing these 2 quantities gives us the above CALTX.ST EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 5.4x - 16.7x | 10.7x |
| Forward P/E multiples | 5.9x - 10.6x | 9.6x |
| Fair Price | (38.40) - (66.21) | (63.32) |
| Upside | -118.5% - -131.8% | -130.4% |
| Date | EV/EBITDA |
| 2024-10-10 | -35.90 |
| 2024-10-09 | -35.60 |
| 2024-10-08 | -35.56 |
| 2024-10-07 | -35.53 |
| 2024-10-04 | -35.66 |
| 2024-10-03 | -35.63 |
| 2024-10-02 | -35.60 |
| 2024-10-01 | -35.70 |
| 2024-09-30 | -35.70 |
| 2024-09-27 | -35.60 |
| 2024-09-26 | -35.63 |
| 2024-09-25 | -35.63 |
| 2024-09-24 | -35.60 |
| 2024-09-23 | -35.66 |
| 2024-09-20 | -35.63 |
| 2024-09-19 | -35.60 |
| 2024-09-18 | -35.60 |
| 2024-09-17 | -35.60 |
| 2024-09-16 | -35.63 |
| 2024-09-13 | -35.60 |
| 2024-09-12 | -35.80 |